Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. Sep 2008 - Int. J. Oncol.; 33(4):1019-6439 [PMID:18813797] [Janke M] [Peeters B] [Zhao H] [de Leeuw O] [Moorman R] [Arnold A] [Ziouta Y] [Fournier P] [Schirrmacher V]
Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Nov 2007 - Gene Ther.; 14(23):0969-7128 [PMID:17914407] [Janke M] [Peeters B] [de Leeuw O] [Moorman R] [Arnold A] [Fournier P] [Schirrmacher V]
Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Jun 2006 - Int. J. Cancer; 119(2):0020-7136 [PMID:16470838] [Fiola C] [Peeters B] [Fournier P] [Arnold A] [Bucur M] [Schirrmacher V]
Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein. Jul 2005 - Int. J. Oncol.; 27(2):1019-6439 [PMID:16010418] [Bian H] [Fournier P] [Peeters B] [Schirrmacher V]
Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus. Feb 2005 - Cancer Gene Ther.; 12(3):0929-1903 [PMID:15605075] [Bian H] [Fournier P] [Moormann R] [Peeters B] [Schirrmacher V]
Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein. Jan 2005 - Int. J. Oncol.; 26(2):1019-6439 [PMID:15645128] [Bian H] [Fournier P] [Moormann R] [Peeters B] [Schirrmacher V]
